Intravitreous vascular endothelial growth factor (VEGF) inhibitor therapy for tamoxifen induced macular edema

Seminars in Ophthalmology

Volumn 22, Issue 2, 2007, Pages 87-88

  Bourla, Dan H ^a,b   Gonzales, Christine R ^a   Mango, Charles W ^a   Moral, Joel N ^a   Wirthlin, Robert S ^a   Schwartz, Steven D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

Author keywords

Macular edema; Pegaptanib; Retinopathy; Tamoxifen; VEGF

Indexed keywords

PEGAPTANIB; TAMOXIFEN; VASCULOTROPIN INHIBITOR;

ADULT; ARTICLE; ASTROCYTOMA; CASE REPORT; CLINICAL EXAMINATION; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA EDEMA; VISUAL ACUITY;

ANTINEOPLASTIC AGENTS, HORMONAL; APTAMERS, NUCLEOTIDE; ASTROCYTOMA; BRAIN NEOPLASMS; HUMANS; INJECTIONS; MACULAR EDEMA, CYSTOID; MALE; MIDDLE AGED; TAMOXIFEN; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 34250347204     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530701418524     Document Type: Article

References (4)

1. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 1997; 24:65-70.
2. McKeown CA, Swartz M, Blom J, Maggiano M Tamoxifen retinopathy. Br J Ophthalmol 1981; 65:177-9.
3. Kaiser-Kupfer MI, Kupfer C, Rodrigues MM. Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology 1981; 88:89-93.
4. Cunningham ET Jr, Adamis AP, Altaweel M et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112:1747-57.